SCHEMBL16666231

SCHEMBL16666231

NC(=O)C12CC3CC(C1)C(NC(=O)C1(Nc4cccc(Cl)c4)CC1)C(C3)C2

nearest known ligand 0.70

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 20/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16684439 0.85 HSD11B1 (0.74) HSD11B1
SCHEMBL16666467 0.84 HSD11B1 (0.73) HSD11B1
SCHEMBL16684456 0.82 HSD11B1 (1.00) HSD11B1
SCHEMBL16666487 0.82 HSD11B1 (1.00) HSD11B1
SCHEMBL234347 0.79 HSD11B1 (0.70) HSD11B1
SCHEMBL16666954 0.78 HSD11B1 (0.74) HSD11B1
SCHEMBL14680722 0.77 HSD11B1 (0.78) HSD11B1
SCHEMBL2025779 0.75 HSD11B1 (0.56) HSD11B1
SCHEMBL15891890 0.75 HSD11B1 (0.83) HSD11B1
SCHEMBL16666600 0.74 HSD11B1 (1.00) HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2865664-A1 NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT BAMICHEM CO., LTD (KR) 2015-04-29 — — EP claimed
US-9464044-B2 Compound having ability to inhibit 11Beta-HSD1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient AHN-GOOK PHARMACEUTICAL CO., LTD. (KR) 2016-10-11 — — US disclosed
US-20150210635-A1 NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) 2015-07-30 — — US disclosed
EP-2865664-A1 NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT BAMICHEM CO., LTD (KR) 2015-04-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210635-A1 NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT HSD11B1, HSD11B2, HSD17B1 HSD11B1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback